Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (23463)	7/24/1998 12:15:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Peter, I think that more details are required to compare deals (including how much effort AGN has to put into preclinical and clinical development, as well as the royalty rate). Moreover, LGND's deal with LLY coupled with WLA's Rezulin problems and SBH's new drug may have put some pressure on WLA. Don't forget, LGND had talked to WLA last summer and I believe that negotiations had progressed fairly far, but WLA didn't want to put up ant up front money. There is no equity mentioned in this deal, but there is no up front money either. LGND's need for cash is markedly different than AGN's.